or
forgot password

Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer


Phase 2
18 Years
N/A
Not Enrolling
Female
Ovarian Neoplasms

Thank you

Trial Information

Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer


This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to
Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring
this trial.


Inclusion Criteria:

- Must have evidence of ovarian cancer measurable by computed
tomography (CT) scan or by CA125 blood levels- No radiation therapy in last 4 weeks- No
chemotherapy in last 24 weeks - No immunotherapy in last 4 weeks- Good response after
previous treatment with carboplatin or cisplatin and then the ovarian cancer got worse
again after at least 6 months- Additional criteria determined at screening visit
Exclusion Criteria:- Having had more than one treatment regimen with carboplatin or
cisplatin- Prior treatment with other epothilones (e.g. ixabepilone)- Use of any
investigational drug in the last 4 weeks- Previous radiation to the whole pelvis-
Symptomatic brain tumors requiring radiation to the brain - Active infection- Pregnant or
breast feeding- Additional criteria determined at screening visit

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response to treatment with ZK-Epo after 6 cycles

Outcome Time Frame:

After 6 cycles

Safety Issue:

No

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

United States: Food and Drug Administration

Study ID:

91476

NCT ID:

NCT00325351

Start Date:

August 2006

Completion Date:

March 2009

Related Keywords:

  • Ovarian Neoplasms
  • Ovarian cancer
  • Ovarian neoplasms, epithelium
  • Neoplasms
  • Ovarian Neoplasms

Name

Location

Albany, Georgia  31701
Phoenix, Arizona  85012
Fountain Valley, California  92708
Cleveland, Ohio  44195
Nashville, Tennessee  37203-1632
McLean, Virginia  22101
Little Rock, Arkansas  72205-7199
Albuquerque, New Mexico  87131-5636
Baltimore, Maryland  21287
Charlotte, North Carolina  
Indianapolis, Indiana  
Tulsa, Oklahoma